IDP Pharma has closed a 1,4M€ seed investment round, following a pre-seed round of 0,1M€ (June 2015), which adds up to the ca 0,6M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ).

The company will allocate the capital to advance the preclinical development of its prioritized product – a first in class drug for multiple mieloma treatment, to set up new discovery programs, and to continue developing its technological platform.

Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream